In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.

Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more, this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.

In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.

Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.

Guests:

• Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
• Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust

Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.

Guests:

• Professor Mark Lowdell, CSO InMune Bio Inc
• Luc Henry, Founder and CEO at Limula